706 related articles for article (PubMed ID: 18597953)
1. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
[TBL] [Abstract][Full Text] [Related]
2. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
[TBL] [Abstract][Full Text] [Related]
3. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
4. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
[TBL] [Abstract][Full Text] [Related]
5. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes.
Stone NN; Stock RG; Cesaretti JA; Unger P
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):355-60. PubMed ID: 19632069
[TBL] [Abstract][Full Text] [Related]
6. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
7. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
[TBL] [Abstract][Full Text] [Related]
8. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
9. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy.
Stock RG; Cesaretti JA; Hall SJ; Stone NN
BJU Int; 2009 Dec; 104(11):1631-6. PubMed ID: 19493260
[TBL] [Abstract][Full Text] [Related]
12. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
13. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
15. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.
Seung SK; Kroll S; Wilder RB; Posner MD; Roach M
Cancer J Sci Am; 1998; 4(3):168-74. PubMed ID: 9612598
[TBL] [Abstract][Full Text] [Related]
16. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
[TBL] [Abstract][Full Text] [Related]
17. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
18. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
Vargas CE; Martinez AA; Boike TP; Spencer W; Goldstein N; Gustafson GS; Krauss DJ; Gonzalez J
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):416-23. PubMed ID: 16879929
[TBL] [Abstract][Full Text] [Related]
19. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
